Results from a phase 3 clinical trial have shown that pembrolizumab, an immunotherapy drug, can significantly prolong overall survival in patients with kidney cancer. This groundbreaking study, known as the KEYNOTE-564 trial, is the first in fifty years to demonstrate an overall survival benefit from an adjuvant therapy in patients with kidney cancer.

During the trial, pembrolizumab was given to patients with clear-cell renal-cell carcinoma (ccRCC) who were at high risk for recurrence after surgery. The results showed a 38% reduction in the risk of death compared to a placebo. This means that not only does pembrolizumab delay recurrences, but it also helps patients live longer.

Kidney cancer is known for its high rate of recurrence, with 30 to 50% of patients experiencing recurrences after surgery. Metastatic disease, which is usually incurable, often results from these recurrences. Therefore, finding ways to reduce recurrences and prolong survival has been a priority for researchers for decades.

The success of this trial offers hope to kidney cancer patients and opens the door to further research and development of immunotherapies. Pembrolizumab, which targets a molecular pathway that cancer cells use to evade the immune system, could potentially revolutionize the treatment of kidney cancer and improve outcomes for patients in the future.